ALLMedicine™ Hyperviscosity Syndrome Center
Research & Reviews 51 results
Journal of Clinical Apheresis; Green AP, Gonzalez AC et. al.
May 5th, 2021 - Hyperviscosity syndrome (HVS) is a life-threatening syndrome caused by high concentrations of large plasma proteins like IgM, rheumatoid factor, and other immune complexes, leading to increased blood viscosity and symptoms such as visual abnormali...
Microvascular Research; Caimi G, Lo Presti R et. al.
Apr 17th, 2021 - Hyperviscosity syndrome is a clinical condition characterized by the slowing of blood flow through the vessels and it may be associated with several diseases. The nosographic classification of primary hyperviscosity conditions (Wells classificatio...
Otology & Neurotology : Official Publication of the Ameri... Dumberger LD, Hwa TP et. al.
Mar 31st, 2021 - To perform a systematic review of sensorineural hearing loss (SNHL) in hematologic malignancy; to describe an illustrative case of urgent cochlear implantation for bilateral profound SNHL and vestibular hypofunction in hyperviscosity syndrome; to ...
European Journal of Ophthalmology; Lai CC, Chang CH
Mar 16th, 2021 - To present a 5-year mortal case of Waldenström's macroglobulinemia-related retinopathy and serous macular detachment. A 63-year-old man, with unremarkable medical history, presented with bilateral decreased vision for 2 months. Fundus examination ...
European Journal of Ophthalmology; Merz T, Marchesoni I et. al.
Feb 20th, 2021 - To report a case of good clinical response to plasmapheresis as therapy for a bilateral hyperviscosity syndrome related retinopathy in a young patient with undiagnosed multiple myeloma (MM). Case report. A 48-year-old caucasian man, previously dia...
News 3 results
Feb 1st, 2021 - Waldenström macroglobulinemia (WM) is an indolent subtype of non-Hodgkin lymphoma (NHL) that affects small lymphocytes. WM is rare, accounting for approximately 2% of hematologic malignancies with 1500 cases diagnosed per year in the United States...
Apr 6th, 2018 - Similarly increased odds of no treatment were reported for patients with comorbidities and poor performance status indicators. “In a subset of older and frail patients, the risks of treatments approved for [multiple myeloma] might outweigh the ben.
Mary Ellen Schneider
Nov 21st, 2017 - Four to six cycles of bendamustine/rituximab is the primary regimen of choice for symptomatic, treatment-naive patients with Waldenström macroglobulinemia, especially when rapid control is needed for bulky disease, according to treatment guideline.